Maxim Group set a $4.00 target price on Celsion Corp. (NASDAQ:CLSN) in a research report report published on Tuesday. The brokerage currently has a a buy rating on the stock.

Separately, HC Wainwright reiterated a buy rating and set a $3.00 price target on shares of Celsion Corp. in a report on Tuesday, July 12th.

Celsion Corp. (NASDAQ:CLSN) opened at 1.14 on Tuesday. The company has a 50 day moving average of $1.22 and a 200-day moving average of $1.34. The stock’s market capitalization is $29.42 million. Celsion Corp. has a 12-month low of $1.04 and a 12-month high of $2.31.

Celsion Corp. (NASDAQ:CLSN) last issued its earnings results on Monday, August 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.02. Celsion Corp. had a negative return on equity of 103.07% and a negative net margin of 3,966.14%. On average, equities research analysts forecast that Celsion Corp. will post ($0.83) earnings per share for the current year.

A hedge fund recently raised its stake in Celsion Corp. stock. Sabby Management LLC boosted its stake in Celsion Corp. (NASDAQ:CLSN) by 7,986.5% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,519,365 shares of the company’s stock after buying an additional 1,500,576 shares during the period. Sabby Management LLC owned about 6.48% of Celsion Corp. worth $1,930,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 15.19% of the company’s stock.

About Celsion Corp.

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

5 Day Chart for NASDAQ:CLSN

Receive News & Stock Ratings for Celsion Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corp. and related stocks with our FREE daily email newsletter.